Benign prostatic hyperplasia BPH is the medical condition typically observed in old aged men characterized by enlargement of the prostate gland resulting into squeezing of the urethra. BPH can cause problems in the urinary bladder, kidney and urinary tract. It is often treated prescribing doses of alpha-blockers, 5-alpha reductase, or combination of other drugs. For severe conditions, minimally invasive or laser therapies are also performed to treat BPH. The rise in awareness regarding urological diseases is contributing to the growth of BPH and prostate treatment market.
GlobalData uses the information in this form to provide you with occasional updates on new products and reports in accordance with your preferences. Trending Prosstate. Retirement Planner. Metabolic Disorder. Cash and Carries and Warehouse Clubs.
Tracy lester realtor. Quick Links
We realize the need and requirement of Rubs clit on table clients and provide reports tailored in accordance to the particular industry segment. We provide our clients and users with extensively curated research and study report. Spain 5. According Prostate treatment market market experts, biological therapy is the first line of treatment in order to reduce androgens in the body Testosterone, Dihydrotestosterone as they stimulate the growth of the prostate cancer cells. Australia 5. Increased prevalence of prostate cancer due to rapidly aging population, growing awareness among people, rising treatment demand, and availability of new treatments are drivers boosting market growth. Treatjent Cancer Market — Market Outlook 3. Rest of Asia Pacific 5. This market needs novel drugs that will address the unmet needs low cost and improved survival time. Why should I purchase this report? Value Chain Analysis Fig. The Asia-Pacific will occupy for more market share in following years, especially in China, also fast Prostage India and Southeast Asia regions. It is estimated that nearly 30, men died because of prostate cancer in Every 7 out of 10 customers request tailored reports.
This report on global prostate cancer treatment market studies various drugs used for treatment of prostate cancer along with pipeline analysis of upcoming potential drugs.
- The global prostate cancer therapeutics market is expected to reach USD
- Market Synopsis of Prostate cancer market:.
- Benign prostatic hyperplasia BPH is the medical condition typically observed in old aged men characterized by enlargement of the prostate gland resulting into squeezing of the urethra.
- Prostate cancer is the second most frequently diagnosed cancer in the world and the fifth leading cause of cancer death among men.
- Prostate Cancer Treatment Industry
Your data will never be shared with third parties, however we may send you information from time to time about related third party products that may be of interest to you. You may contact us at any time to opt-out. GlobalData uses the information in this form to provide you with occasional updates on new products and reports in accordance with your preferences. You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you.
The prostate cancer competitive landscape is experiencing a substantial change. Given that Zytiga and Xtandi are limited by the insurgence of acquired resistance, physicians will face the critical issue of determining the best treatment sequence for subsequent lines of therapy, most notably in the mCRPC setting. Additionally, companies are now moving toward a more personalized approach in prostate cancer, targeting mCRPC patients with specific genetic signatures, such as PTEN loss and DNA repair abnormalities.
GlobalData expects these biomarker-driven drug development strategies to induce further patient stratification and to add complexity to the CRPC treatment algorithm. Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from to Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled. Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The main driver of the growth of the prostate cancer market will be the continued uptake of second-generation hormonal agents into mHNPC and nmCRPC, where the extended treatment duration will drive overall sales. The second strongest driver will be the increasing number of incident cases.
To gain approval and obtain reimbursement, it is essential for pipeline drugs to demonstrate greater efficacy overall survival compared with available agents. The earlier use of these agents in the hormone-sensitive disease may negatively affect the uptake of this combination in the later line of treatment, mCRPC.
Due to concerns related to the high annual cost of therapy, GlobalData expects heavy generic erosion of Zytiga when abiraterone generics launch, starting in Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global prostate cancer market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Please complete the form below, you will then be provided immediate access to the pages you have requested.
Contact Careers Subscribe Investor Centre. Industry Banking. Construction Equipment. Construction Materials. Construction Projects. Construction Services. Alcoholic Beverages. Automotive Products. Baby Care. Household Care. Non-Alcoholic Beverages. Pet Care. Tobacco and Tobacco Products. Ordnance and Guns. Land Systems. Electronics, IT and Others. Homeland Security.
Food Service. Medical Devices. Anesthesia and Respiratory Devices. Cardiovascular Devices. Dental Devices. Diabetes Care Devices. Diagnostic Imaging.
Drug Delivery Devices. ENT Devices. General Surgery. Healthcare IT. Hospital Supplies. In Vitro Diagnostics. Nephrology and Urology Devices. Neurology Devices. Ophthalmic Devices. Orthopedic Devices. Wound Care Management. Oil and Gas. Central Nervous System. Ear Nose Throat Disorders. Genitourinary Disorders. Hormonal Disorders.
Infectious Disease. Metabolic Disorder. Mouth And Dental Disorders. Non Malignant Disorders. Nutritional Disorders. Other Diseases. Women's and Male Health. Smart Grid. Marine Energy. Apparel, Accessories, Luggage and Leather Goods.
Cash and Carries and Warehouse Clubs. Drug Stores and Health and Beauty Stores. Duty Free Retailing. Electrical and Electronics. Food and Drinks Specialists. Furniture and Floor. General Retailers. Home and Garden. Hypermarkets, Supermarkets and General Merchandise Retailers.
Online Retailing. Sports and Leisure. Financial Markets. Scope Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Key Highlights The main driver of the growth of the prostate cancer market will be the continued uptake of second-generation hormonal agents into mHNPC and nmCRPC, where the extended treatment duration will drive overall sales.
Europe 5. The global Prostate Cancer Treatment market report dives deep into the market and garners the slimmest of information to provide the most comprehensive findings and insights. Increased prevalence of prostate cancer due to rapidly aging population, growing awareness among people, rising treatment demand, and availability of new treatments are drivers boosting market growth. About Prostate Cancer Treatment Market: Prostate cancer is the most common cancer among men, the key risk factors for prostate cancer development is being old age, genetic, obesity and race. Our Clients. Ask for free product review call with the author Share your specific research requirments for a customized report Request for due diligence and consumer centric studies Request for study updates, segment specific and country level reports Request for Customization. Prostate Cancer Market - Competitive Trends 6.
Prostate treatment market. Key questions answered by the report
Market Overview Prostate cancer is the second most frequently diagnosed cancer in the world and the fifth leading cause of cancer death among men. Market Drivers Increasing disease prevalence will act as the primary driver for market growth.
Market Segmentation The Global Prostate Cancer market report segments the market by therapy, by end-user, and by region. Why should I purchase this report? Identify commercial opportunities by analyzing trends and co-development deals. Product mapping in excel for crucial Prostate Cancer products of all major market players. Who can benefit from this report? Prostate Cancer Market — Methodology and Scope 1.
Prostate Cancer Market — Industry Trends 2. Prostate Cancer Market — Market Outlook 3. Prostate Cancer Market - Product-based Analysis 4. North America 5. The USA 5. Canada 5. Mexico 5. Europe 5. Germany 5. France 5. The UK 5. Italy 5. Spain 5. Rest of Europe 5. Asia Pacific 5. China 5. Japan 5. India 5. Australia 5. Rest of Asia Pacific 5. South America 5.
Brazil 5. Argentina 5. Rest of South America 5. Prostate Cancer Market - Competitive Trends 6. Example coming under targeted therapy is Xofigo. The global prostate cancer treatment market is highly demanding. There are eight plus molecules in phase III of clinical trials and 26 molecules in phase II; of these 21 are small molecules. North America and Europe dominate the market. Rising prevalence of disease, world class diagnosis techniques, health awareness among the people, and increasing geriatric population drive the market in these regions.
Asia Pacific is expected to be the fastest growing market during the forecast period. Rising awareness about the disease, government support, and advanced diagnosis are factors boosting the market. Increased investments in research and development of immunotherapy and targeted therapies is creating significant pipeline.
This is one of the factors likely to trigger market growth in Asia Pacific. The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions.
By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The report has been compiled through extensive primary research through interviews, surveys, and observations of seasoned analysts and secondary research which entails reputable paid sources, trade journals, and industry body databases. A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Prostate Cancer Therapeutics Market Size | Industry Report,
The prostate gland is located in the pelvis, below the bladder and in front of the rectum. Prostate cancer begins when normal cells in the prostate begin to multiply uncontrollably. The scope of the study is limited to revenue generated by various diagnostic and therapeutic products used in the management of benign prostatic hyperplasia, prostatic adenocarcinoma, and small cell carcinoma, among other types of prostate cancer.
Report scope can be customized per your requirements. Click here. Prostate-specific Antigen PSA is a protein produced by prostate cells. Therefore, the PSA test is performed to diagnose prostate cancer PCa in men and for follow-up post treatment to check if the cancer relapses. Medicare and several private insurers provide coverage for an annual PSA test for all Medicare-eligible men aged 50 and older. The PSA testing is gaining popularity among clinicians and hospitals, owing to the increasing number of people being affected by prostate cancer.
PSA testing is anticipated to reduce the likelihood of death from prostate cancer. Refinements of the prostate-specific antigen PSA test have been developed to reduce the number of false positive results. Therefore, due to the rising prevalence of prostate cancer, the market is expected to witness high growth rate, over the forecast period.
To understand key trends, Download Sample Report. Hence, it is considered to have an early diagnosis of the condition. In case of the treatment, the early stages of prostate cancer are treated by radiation therapy and for the late stages, where it has spread beyond the prostate gland, hormone therapy, chemotherapy, and or immunotherapy treatments, are recommended.
In the case of benign prostatic hyperplasia BPH , resectoscopy is the major treatment procedure. Zytiga and Xtandi are the major therapeutics that are used for treatment. Zytiga is approved for the treatment of metastatic castration-resistant prostate cancer mCRPC. With promising pipeline drugs, such as Apalutamide, the market of therapeutics is expected to increase. To understand geography trends, Download Sample Report.
Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as a major player lies primarily within specific product markets. Key players in the market include Abbott Laboratories, Astellas Inc. Hoffmann-La Roche AG, among others. Table Of Contents Download Sample. Base Year: Fastest Growing Market: Asia Pacific. Largest Market: North America. CAGR: 6. Key Players:.
How do you want us to tailor yours? Customize the Report. The major factor driving the growth of the market studied is aging population and high prevalence rate of prostate cancer.
Prostate cancer is the second most common type of cancer in male population. As per the estimates provided by the American Cancer Society, in , the United States is expected to witness over , new cases of prostate cancer, with over 29, related deaths. One in every nine men is expected to be diagnosed with prostate cancer during his lifetime.
The number of people aged 85 and older is expected to triple from an estimated 6 million of today to nearly 20 million, by The risk of developing prostate cancer increases significantly with age, and rise in geriatric population is one of the leading factors that contribute to the expansion of the market.
Scope of the Report The prostate gland is located in the pelvis, below the bladder and in front of the rectum. Competitive Landscape Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as a major player lies primarily within specific product markets. Table of Contents 1. Please Enter a Valid Message!